Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community | Zendy

Rainer H. Böger | Zendy; Lisa Sullivan | Zendy; Edzard Schwedhelm | Zendy; Thomas J. Wang | Zendy; Renke Maas | Zendy; Emelia J. Benjamin | Zendy; Friedrich Schulze | Zendy; Vanessa Xanthakis | Zendy; Ralf A. Benndorf | Zendy; Ramachandran S. Vasan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community

Author(s) -

Rainer H. Böger,

Lisa Sullivan,

Edzard Schwedhelm,

Thomas J. Wang,

Renke Maas,

Emelia J. Benjamin,

Friedrich Schulze,

Vanessa Xanthakis,

Ralf A. Benndorf,

Ramachandran S. Vasan

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.838268

Subject(s) - medicine , asymmetric dimethylarginine , disease , cardiology , incidence (geometry) , intensive care medicine , arginine , chemistry , biochemistry , amino acid , physics , optics

Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, induces endothelial dysfunction. Although elevated ADMA has been associated with an increased risk of cardiovascular disease events and death in referral samples, the prognostic significance of ADMA in the community has not been adequately evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research